Efficacy News and Research

RSS

Northwestern scientists develop rapid HIV test for point-of-care diagnosis

A team of Northwestern University scientists spanning disciplines have developed new technology that could lead to the creation of a rapid point-of-care test for HIV infection competitive with traditional lab-based HIV testing in a fraction of the time and without the need for a stressful wait while results are processed or confirmed in a clinical laboratory.

2 Apr 2025

Mount Sinai launches AI center to revolutionize small molecule drug discovery

The Icahn School of Medicine at Mount Sinai has launched the AI Small Molecule Drug Discovery Center, a bold endeavor that harnesses artificial intelligence (AI) to revolutionize drug development.

2 Apr 2025

New drug shows neuroprotective and anti-inflammatory effects in murine models of Alzheimer's

Alzheimer's disease, the most common cause of dementia, is currently incurable. The current drugs available have very limited efficacy and only in mild stages of the disease.

2 Apr 2025

Understanding the phases and treatment options for Peyronie’s disease

The review article titled"Current insights and future directions in Peyronie's disease management: A narrative review", was published on November 12, 2024 in UroPrecision.

2 Apr 2025

ICRAFT platform identifies new targets for cancer immunotherapy

Professor Zeng Zexian's team from the Center for Quantitative Biology at the Peking University Academy for Advanced Interdisciplinary Studies, in collaboration with the Peking University-Tsinghua University Joint Center for Life Sciences, has developed ICRAFT, an innovative computational platform for identifying cancer immunotherapy targets.

1 Apr 2025

Rare sugars curb appetite and mimic diabetes drugs in mice

Rare sugars like D-allulose, D-tagatose, and D-sorbose significantly boosted GLP-1 secretion and suppressed food intake in mice. D-allose also reduced food intake through a unique, GLP-1-independent pathway.

1 Apr 2025

New tool helps predict CAR T therapy outcomes for lymphoma patients

Researchers with City of Hope, one of the largest and most advanced cancer research and treatment organizations in the United States, with its National Medical Center in Los Angeles ranked among the nation's top 5 cancer centers by U.S. News & World Report, and MSK have created a tool that uses machine learning to assess a non-Hodgkin lymphoma (NHL) patient's likely response to chimeric antigen receptor (CAR) T cell therapy before starting the treatment, according to study results published today in Nature Medicine.

1 Apr 2025

Supercharging Next-Gen Antibody Discovery with AI and High-Throughput Experimentation

Automation and machine learning are transforming antibody discovery at LabGenius, with the EVA™ platform enabling rapid, high-throughput experimental processes.

1 Apr 2025

WINREVAIR™ (sotatercept-csrk) reduced the risk of a composite of all-cause death, lung transplantation and hospitalization for pulmonary arterial hypertension (PAH) by 76% compared to placebo in the phase 3 ZENITH trial

Merck, known as MSD outside of the United States and Canada, today announced the first presentation of results from the Phase 3 ZENITH trial evaluating WINREVAIR™ (sotatercept-csrk) compared to placebo in adults with pulmonary arterial hypertension (PAH, Group 1 PH) WHO* functional class (FC) III or IV at high risk of mortality who were on maximum tolerated background PAH therapy. At a median follow-up of 10.6 months (range, 0.3-26.1), WINREVAIR reduced the relative risk of major morbidity and mortality events (the composite of all-cause death, lung transplantation and PAH worsening-related hospitalization of ≥24 hours) by 76% (HR=0.24 [95% CI, 0.13-0.43]; p<0.0001 [1-sided]) compared to placebo.

1 Apr 2025

Trilogy valve demonstrates safety and effectiveness in treating aortic regurgitation

Patients who underwent transcatheter aortic valve replacement (TAVR) with a valve designed to treat aortic regurgitation had an overall mortality rate of just 8.1% at one year, well below the trial's prespecified goal of 25% to show non-inferiority, according to a study presented at the American College of Cardiology's Annual Scientific Session (ACC.25).

31 Mar 2025

Traditional Chinese medicine targets cholesterol metabolism for cancer treatment

Researchers explore how natural compounds in traditional Chinese medicine can modulate cholesterol metabolism to combat cancer.

31 Mar 2025

Research shows clopidogrel as better long-term therapy than aspirin after PCI

People at high risk for recurrent cardiac events following percutaneous coronary intervention (PCI), a procedure to open blocked arteries, experienced significantly better outcomes with clopidogrel rather than aspirin as their long-term antiplatelet therapy, according to research presented at the American College of Cardiology's Annual Scientific Session.

31 Mar 2025

Can natural supplements backfire? Review explains how and why

A new review uncovers how common natural supplements can both protect and endanger health, depending on dose, duration, and delivery—and points to next-gen technologies as the key to unlocking their full therapeutic power.

31 Mar 2025

Food delivery apps can lower salt use with one small change

Researchers tested whether menu design and health messages on a Chinese food delivery app could nudge customers to order lower-salt meals. They found that changing default settings on menus—especially defaulting to "reduced salt"—was more effective than educational messages alone.

30 Mar 2025

Caffeine and beetroot juice beat fatigue in repeated high-intensity runs

Caffeine combined with beetroot juice significantly improves both initial and repeated 1000-meter running performance in non-athlete men. Body fat percentage, sleep duration, and nutrition emerge as key factors influencing endurance outcomes.

30 Mar 2025

Bentracimab reverses ticagrelor's antiplatelet effects during surgery and bleeding events

A drug developed as an antidote to the antiplatelet agent ticagrelor safely and effectively reversed ticagrelor's antiplatelet effects in patients undergoing urgent surgery or experiencing major bleeding, according to a study presented at the American College of Cardiology's Annual Scientific Session (ACC.25).

29 Mar 2025

Rivaroxaban shown to be a viable alternative to warfarin for left ventricular thrombus

At three months of follow-up, patients hospitalized for a serious heart attack who were treated with the oral blood thinner rivaroxaban for a blood clot in the left ventricle did as well as similar patients who received standard treatment with warfarin, an older blood-thinning drug.

29 Mar 2025